

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2007

AVENTIS PHARMA LIMITED

Registered Office : Aventis House, 54/A, Sir Mathuradas Vasanji Road,
Andheri East, Mumbai 400 093

(Rs. Million)

Particulars	Quarter ended 30.06.2007 (Reviewed)	Quarter ended 30.06.2006 (Reviewed)	Half year ended 30.06.2007 (Reviewed)	Half year ended 30.06.2006 (Reviewed)	Year ended 31.12.2006 (Audited)
1 Sales	2,454	2,364	4,719	4,483	9,367
Less : Excise duty recovered	152	136	288	250	527
Sales (Net)	2,302	2,228	4,431	4,233	8,840
2 (a) Income from services rendered	67	12	84	20	47
(b) Interest and Dividend Income	76	53	171	93	277
(c) Other Income	39	35	127	83	147
3 Total Expenditure					
(a) (Increase) /Decrease in Stock in trade	97	76	(131)	(162)	(225)

Particulars	Quarter ended 30.06.2007 (Reviewed)	Quarter ended 30.06.2006 (Reviewed)	Half year ended 30.06.2007 (Reviewed)	Half year ended 30.06.2006 (Reviewed)	Year ended 31.12.2006 (Audited)
(b) Materials	1,039	986	2,301	2,184	4,511
(c) Staff Cost	280	195	490	374	785
(d) Other Expenditure	441	362	832	736	1,562
4 Interest	-	1	-	1	2
5 Depreciation	47	42	92	85	179
6 Profit Before Tax	580	666	1,229	1,211	2,497
7 Provision for Taxation					
- Current	196	217	386	397	838
- Deferred	-	(4)	17	(16)	(74)
- Fringe benefit tax	11	14	20	22	40
8 Net Profit	373	439	806	808	1,693
9 Paid-up Equity Capital (Face Value Rs. 10 per Share)	230	230	230	230	230
10 Reserves excluding Revaluation Reserves	-	-	-	-	5,656

Particulars	Quarter ended 30.06.2007 (Reviewed)	Quarter ended 30.06.2006 (Reviewed)	Half year ended 30.06.2007 (Reviewed)	Half year ended 30.06.2006 (Reviewed)	Year ended 31.12.2006 (Audited)
11 Earnings per Share (Rs.) (not annualised)	16.22	19.09	35.04	35.13	73.51
12 Aggregate of Non-Promoter Shareholding					
- Number of Shares	9,120,955	9,125,820	9,120,955	9,125,820	9,120,955
- Percentage of Shareholding	39.60	39.62	39.60	39.62	39.60

Notes:

- The above Results were approved by the Board of Directors of the Company at its Meeting held on July 17, 2007.
- The break up of Net Sales is as follows:

(Rs. in Million)

	Quarter ended June 30, 2007	Quarter ended June 30, 2006	Growth %	Half Year ended June 30, 2007	Half Year ended June 30, 2006	Growth %
Domestic Sales	1,833	1,712	7.1%	3,539	3,247	9.0%
Export Sales	469	516	-9.1%	892	986	-9.5%
Total Sales	2,302	2,228	3.3%	4,431	4,233	4.7%

- During the first half of 2007, the Company received lower supplies of the anti rabies vaccine Rabipur due to production issues in the manufacturer's plant on account of which the expected growth in the Rabipur distribution business could not be achieved. This resulted in significantly lower sales for the Company.

- The Company has a single business segment namely 'Pharmaceutical Business'.
- Effect of Accounting Standard 15 (Revised) (AS 15) Employee Benefits for the half year ended June 30, 2007 has been considered in the above and additional impact, if any, as at the beginning of the year will be adjusted from the Reserves and Surplus as per transitional provisions of AS 15.
- In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended June 30, 2007.
- The Board of Directors has declared an Interim Dividend of Rs.3.50 per Equity share of Rs. 10 to be paid to those Members whose names appear on the Register of Members of the Company on July 26, 2007, being the Record Date.
- Information on investor complaints is furnished below:

Pending as on April 1, 2007	Received during the quarter	Disposed of during the quarter	Pending as on June 30, 2007
1	2	3	Nil

- The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED
DR. SHAILESH AYYANGAR
MANAGING DIRECTOR